Entrada Therapeutics
TRDA
#6263
Rank
ยฃ0.52 B
Marketcap
ยฃ13.99
Share price
1.79%
Change (1 day)
7.48%
Change (1 year)

P/E ratio for Entrada Therapeutics (TRDA)

P/E ratio as of December 2024 (TTM): -6.82

According to Entrada Therapeutics's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -6.81783. At the end of 2022 the company had a P/E ratio of -4.48.

P/E ratio history for Entrada Therapeutics from 2021 to 2023

PE ratio at the end of each year

Year P/E ratio Change
2022-4.48-40.05%
2021-7.47

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.